Last updated: 2026-10-14 22:18:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Edgewise Therapeutics, Inc. (EWTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37.05, with a market capitalisation of $4.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.25 to $48.51. This page covers its latest market performance, valuation, price trends and company information.
$4.18B | |
$35.93 | |
$48.51 | |
$5.12 | |
$36.28 | |
974.78K | |
1.35M | |
-- | |
$48.51 | |
$14.25 | |
-- | |
-- |
Edgewise Therapeutics, Inc. (EWTX) is trading at $37.06 in after-hours trading as of 2026-10-14 21:41:00, up 2.15% ($0.78) from the regular-session close of $36.28.
After-hours trading shows how investors are pricing EWTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Edgewise Therapeutics, Inc. (EWTX) moved from $40.30 to $37.05, representing a decline of 8.07% ($3.25).
The stock traded between $35.64 and $41.79 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.35 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.5%
EWTX is currently trading at $37.05, placing it 66.5% of the way from its 52-week low of $14.25 to its 52-week high of $48.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 127 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Edgewise Therapeutics, Inc. (EWTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.